Summit Therapeutics Inc.
SMMT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001599298
No open-market purchases or sales by Summit Therapeutics Inc. insiders were filed in the last 90 days; 242 institutions reported holding it in 13F filings for Q2 2026, worth $1.98B in total; no superinvestor holds it.
Q3 2026 data is still coming in (13F filing deadline: Nov 16, 2026), so these numbers are incomplete.
Q3 2026 vs. Q2 2026
How the institutions holding Summit Therapeutics Inc. changed between Q2 2026 and Q3 2026.
All holders in Q3 2026All holders in Q2 2026
| Measure | Q2 2026 | Of which not filed for Q3 2026 | Q3 2026 | Change |
|---|---|---|---|---|
| Holders | 242 | 241 | 3 | +2 |
| Shares | 135.9M | 135.9M | 2.30K | +1.71K (+288.5%) |
| Value | $1.98B | $1.98B | $38.4K | +$29.4K (+326.2%) |
241 institutions that held it in Q2 2026 haven't filed for Q3 2026 yet. Not filing isn't selling, so the changes leave them out.
New holders (2)
Institutions that held Summit Therapeutics Inc. at the end of Q3 2026 but not at the end of Q2 2026.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Versant Capital Management, Inc | 240 | $4.06K | 0.00% |
| Planning Strategies Inc. | 18 | $304 | 0.00% |
Sold out (0)
Institutions that held Summit Therapeutics Inc. at the end of Q2 2026 and filed for Q3 2026 without it.
None.
Not filed for Q3 2026 yet (241)
Institutions that held Summit Therapeutics Inc. at the end of Q2 2026 and haven't filed a 13F for Q3 2026. Not filing isn't selling, so they aren't counted as sold out.
Showing the largest 100 of 241 by value.